Activation of both NLRP3 and NLRP6 contribute to dysbiosis, liver inflammation, and fibrosis via its effector IL-18 has also been demonstrated in several NASH studies. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.